Table 2.
Adverse events of BRAFi and MEKi monotherapy reported in glioma trials.
| BRAFi | MEKi | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dabrafenib (23) | Vemurafenib (25) | Selumetinib (141) | Trametinib (143) | ||||||||
| Toxicity | Any (%) | Grade >=3 | Toxicity | Any (%) | Grade >=3 | Toxicity | Grades 1–2 (%) | Grade >=3 | Toxicity | Any (%) | Grade >=3 |
| Fatigue | 34 | 0 | Arthralgia | 67 | 0 | CK elevated | 68 | 10 | Any | 89 | 44 |
| Rash | 31 | 0 | Melanocytic nevus | 38 | 0 | Hypoalbuminaemia | 62 | 0 | Rash | 38 | 11 |
| Dry skin | 28 | 0 | PPES | 38 | 0 | Dyspnea | 60 | 0 | Paronychia | 38 | 6 |
| Pyrexia | 28 | 0 | Alopecia | 33 | 0 | Duodenal ulcer | 58 | 0 | Xerodermia | 22 | 0 |
| Rash maculopapular | 28 | 9 | Fatigue | 29 | 4 | Rash | 58 | 10 | Diarrhea | 11 | 0 |
| Arthralgia | 25 | 3 | Pruritis | 29 | 0 | Dry skin | 56 | 0 | Dizziness | 11 | 0 |
| Headache | 22 | 0 | Rash | 29 | 13 | Fatigue | 56 | 0 | Eczema | 11 | 6 |
| Vomiting | 22 | 0 | Folliculitis | 25 | 0 | Anemia | 56 | 0 | Fatigue | 11 | 0 |
| Arthralgia | 3 | 3 | Headache | 25 | 0 | Diarrhea | 54 | 4 | Oral mucositis | 11 | 0 |
| DIC | 3 | 3 | Constipation | 21 | 0 | Vomiting | 44 | 0 | Left ventricular dysfunction | 6 | 0 |
| EF decreased | 3 | 0 | Diarrhea | 21 | 0 | Paronychia | 38 | 6 | Pancreatitis | 6 | 6 |
| Hypotension | 3 | 3 | Nausea | 21 | 0 | EF decreased | 38 | 2 | Constipation | 6 | 0 |
CK, creatinine phosphokinase; DIC, disseminated intravascular coagulation; EF, ejection fraction; PPES, palmar-planar erythrodysesthesia.